Literature DB >> 7108208

Human alveolar macrophages: potentiation of their tumoricidal activity by liposome-encapsulated muramyl dipeptide.

S Sone, E Tsubura.   

Abstract

Homogeneous preparations of human alveolar macrophages (AM) were obtained by bronchoalveolar lavage of the lungs of healthy nonsmokers. These AM exhibited a low level of spontaneous cytolytic activity against allogeneic A375 melanoma cells. Tumoricidal activity of AM could be generated and/or augmented by incubation in vitro with either lipopolysaccharides (LPS) or muramyl dipeptide (MDP). MDP derivatives were encapsulated within multilamellar (MLV) liposomes composed of phosphatidylcholine-phosphatidylserine (PC/PS). Dose-response experiments established that liposome-encapsulated MDP augmented the tumoricidal activity of AM at concentrations about 100 times lower than free MDP in the medium. AM activated by MLV containing MDP destroyed allogeneic tumor cell lines, but did not affect cultures of normal, non-neoplastic cells. An inactive derivative, MDP-L, encapsulated in MLV liposomes did not potentiate the tumoricidal activity of AM. We conclude that human AM respond to MDP in vitro and that liposomes containing MDP are far more efficient than unencapsulated, free MDP for enhancing the tumoricidal activity of human AM.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7108208

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  17 in total

1.  Potentiation of direct antitumor cytotoxicity and production of tumor cytolytic factors in human blood monocytes by human recombinant interferon-gamma and muramyl dipeptide derivatives.

Authors:  S Sone; G Lopez-Berestein; I J Fidler
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

2.  Activation of antitumor properties in alveolar macrophages from protein-calorie malnourished rats.

Authors:  S Mutsuura; S Sone; E Tsubura; K Tachibana; Y Kishino
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

3.  Induction of tumouricidal leucocytes by the intranasal application of MTP-PE, a lipophilic muramyl peptide.

Authors:  A F Brownbill; D G Braun; P Dukor; G Schumann
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

4.  Immunostimulation. Clinical and experimental perspectives.

Authors:  J Drews
Journal:  Klin Wochenschr       Date:  1984-03-15

5.  A dried preparation of liposomes containing muramyl tripeptide phosphatidylethanolamine as a potent activator of human blood monocytes to the antitumor state.

Authors:  S Sone; T Utsugi; P Tandon; M Ogawara
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

6.  Prevention of oncogenic viral infections in mice with CGP 11637, a synthetic muramyl dipeptide analog.

Authors:  H F Acevedo; R B Raikow; H O Acevedo; T F Delgado; M Pardo
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

7.  Stimulation of macrophage protease secretion via liposomal delivery of muramyl dipeptide derivatives to intracellular sites.

Authors:  K Mehta; R L Juliano; G Lopez-Berestein
Journal:  Immunology       Date:  1984-03       Impact factor: 7.397

8.  Activation by a new synthetic acyltripeptide and its analogs entrapped in liposomes of rat alveolar macrophages to the tumor cytotoxic state.

Authors:  S Sone; S Mutsuura; M Ogawara; T Utsugi; E Tsubura
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

9.  Further studies on the differences in cytotoxicity of human peripheral blood monocytes and bronchoalveolar macrophages for cultured human lung cells.

Authors:  S Swinburne; M Moore; P Cole
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

10.  Synergistic effect of glucantime and a liposome-encapsulated muramyl dipeptide analog in therapy of experimental visceral leishmaniasis.

Authors:  L E Adinolfi; P F Bonventre; M Vander Pas; D A Eppstein
Journal:  Infect Immun       Date:  1985-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.